Immunogenicity assessment is a critical safety attribute for biotherapeutics undergoing clinical development.
Dr. Kurt Sales Appointed as Chief Scientific Officer at Agilex Biolabs Kurt Sales as Chief Scientific Officer will lead future...
Learn how to improve Bioanalytical clinical outcomes by performing MetID characterisation. Leading experts Heather Heading and...
Large Molecule Facility Doubles Size of Australia’s Top Bioanalytical Laboratory Agilex Biolabs has launched its new laborato...
Agilex Biolabs provides world-class toxicology services via its purpose-built GLP compliant facility in Brisbane, Australia. In co...
This year, we at Agilex Biolabs celebrate our 25th year supporting Biotechs’ drug development programs ...
Agilex Biolabs Pty Ltd has been purchased by one of Australia’s leading healthcare companies, Healius Limited
With increasingly novel drug development programs, meaningful collection of subject samples has never been more relevant. Don’t let potential analyte instability mislead your program as it gets underway, causing costly time delays
Agilex Biolabs Congratulates VGI Health Technology Limited for successful filing of a new PCT Patent Application on Transmucosal Delivery of Tocotrienols
With the integration of leading toxicology company TetraQ into Agilex Biolabs’ service offering, Agilex Biolabs is now the only...